Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

New number of shares and votes in Q-linea AB (publ)

Q-Linea
Download the release

The number of shares and votes in Q-linea AB (publ) (the "Company") has changed during the month of July following the completion of the issue of equalization shares and the subsequent reverse share split (1:1000). The number of shares and votes in the Company amounts to 6,436,873 as of July 31, 2025.

As of 31 July 2025, the total number of shares in the Company amounts to 6,436,873 shares (previously 6,430,039,725 shares) with one vote each. All shares are ordinary shares. The share capital amounts to SEK 64,368,730 (previously 64,300,397.25). A reduction of the share capital by SEK 63,725,042.70, as resolved at the Annual General Meeting on 26 June 2025, is currently being processed by the Swedish Companies Registration Office. Q-linea AB holds 329 of its own shares as of 31 July 2025.

For more information, please contact:


Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea


Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

This information is information that Q-linea is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-07-31 08:30 CEST.

Attachments


New number of shares and votes in Q-linea AB (publ)

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.